Avandaryl for first- and second-Line treatment of type 2 diabetes

Published: 2006-08-25 06:57:00

Updated: 2006-08-25 06:57:00

The Korea Food and Drug Administration said it has approved GlaxoSmithKline's Avandaryl for use as an adjunct to diet and exercise to improve glycemic control in patients with type 2 diabetes mellitus who are already receiving rosiglitazone plus a sulfonylurea or who are not adequately controlled...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK